T2 Biosystems, a medical diagnostic company based in Lexington, Massachusetts, has been granted a conditional extension to remain listed on the Nasdaq Stock Market. The Nasdaq Hearings Panel issued the decision on March 11, 2024, allowing T2 Biosystems to continue its listing, provided it meets the Nasdaq's Market Value requirement by May 20, 2024. The company had previously been notified on November 20, 2023, that it did not meet the minimum $35 million Market Value for 30 consecutive business days, violating Nasdaq Listing Rule 5550(b)(2). Following the delisting notice, T2 Biosystems appealed and attended a hearing on February 15, 2024. The company is now required to maintain a closing Market Value of at least $35 million for ten consecutive business days to comply with the Nasdaq's terms. However, there is no certainty that T2 Biosystems will achieve this compliance within the given timeframe.

T2 Biosystems, a medical diagnostic company based in Lexington, Massachusetts, has been granted a conditional extension to remain listed on the Nasdaq Stock Market. The Nasdaq Hearings Panel issued the decision on March 11, 2024, allowing T2 Biosystems to continue its listing, provided it meets the Nasdaq's Market Value requirement by May 20, 2024. The company had previously been notified on November 20, 2023, that it did not meet the minimum $35 million Market Value for 30 consecutive business days, violating Nasdaq Listing Rule 5550(b)(2). Following the delisting notice, T2 Biosystems appealed and attended a hearing on February 15, 2024. The company is now required to maintain a closing Market Value of at least $35 million for ten consecutive business days to comply with the Nasdaq's terms. However, there is no certainty that T2 Biosystems will achieve this compliance within the given timeframe.